INMAZEB FDA approval date

The FDA approved INMAZEB on 14 Oct 2020.

FDA approval date
14 Oct 2020

Drug identity has not yet been verified against registry records

Also recorded as ATOLTIVIMAB; MAFTIVIMAB; ODESIVIMAB

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2020-10-14DayINMAZEBFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761169", "applicant_as_listed_by_fda": "REGENERON PHARMACEUTICALS", "brand_names": ["INMAZEB"], "active_ingredients": ["ATOLTIVIMAB", "MAFTIVIMAB", "ODESIVIMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201014", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026